Skip to main
OBIO

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Hldgs is poised for long-term success based on its high-potential product candidates, including AVIM Therapy with Breakthrough Device Designation, and Virtue SAB, which has shown promising results in clinical trials. The company's strong partnerships and recent financial transactions have strengthened its balance sheet and positioned it for future success. However, risks such as potential patent disputes and the need for regulatory approvals may pose challenges that could impact the company's financial performance and valuation in the short term.

Bears say

Orchestra BioMed Hldgs is highly dependent on partnerships for commercial success and faces intense competition in the medical device market. The company also has limited clinical data and may face legal challenges to protect their products. The success of their products is subject to regulatory approvals and may be impacted by the rapidly changing technological market and intense competition in the industry. As a financial analyst, this combination of risks and uncertainties leads to a negative outlook on the company's stock.

OBIO has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 4 analysts, OBIO has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.